Department of Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Division of Cardiology, Department of Medicine, University of Michigan, University of Michigan Frankel Cardiovascular Center, 1500 East Medical Center Drive, CVC #2709, Ann Arbor, MI 48109, USA.
Cardiol Clin. 2019 Nov;37(4):505-523. doi: 10.1016/j.ccl.2019.07.015.
Cardiovascular effects of cancer therapies are of concern. Prediction, diagnosis, and management of cardiotoxicity is a challenge. Cardiovascular biomarkers are being studied in relationship to cancer therapy, showing promise in detection and prevention of cardiotoxicity. We summarize the use of biomarkers in cardio-oncology and presents recommendations for their use. Troponins and natriuretic peptides are the most commonly used biomarkers. High-quality evidence supporting their use is lacking. Biomarkers can be incorporated into a detection strategy for cardiotoxicity. Large, well-powered studies are needed to delineate care strategies using biomarkers in the prediction and management of the cardiovascular effects of cancer therapy.
癌症治疗的心血管影响令人关注。预测、诊断和管理心脏毒性是一项挑战。目前正在研究心血管生物标志物与癌症治疗的关系，这些标志物在心脏毒性的检测和预防方面显示出了一定的前景。我们总结了生物标志物在肿瘤心脏病学中的应用，并提出了其应用建议。肌钙蛋白和利钠肽是最常用的生物标志物。但目前缺乏支持其应用的高质量证据。生物标志物可被纳入心脏毒性的检测策略中。需要进行大型、强有力的研究，以明确使用生物标志物预测和管理癌症治疗的心血管影响的护理策略。
